Cancer Biomarkers Market Set to Soar to USD 28.2 Billion by 2026

-

The global cancer biomarkers market is projected to reach USD 28.2 billion by 2026 from USD 12.4 billion in 2021, at a CAGR of 17.7% during the forecast period. Growth in the cancer biomarkers market is mainly driven by factors such as the increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers. However, patent protection of cancer biomarkers and limited battery life are the major factors hampering the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202

Opportunity: Personalized medicine

Personalized medicine identifies the most beneficial treatment path for individual patients. Cancer biomarkers play a very important role in certain aspects of personalized medicine. Consumables used in cancer biomarker testing enable the identification of these diseases. Cancer biomarker diagnostic products are also used as companion diagnostics for several investigational therapies. Thus, the field of personalized medicine is expected to offer potential growth opportunities for players operating in the market.

Challenge: Challenges associated with cancer biomarker validation

The cancer biomarker validation process includes evaluating assays or measuring performance characteristics such as sensitivity, specificity, and reproducibility. Validation is critical for establishing cancer biomarkers as reliable tools to support drug development, medical care, and biopharmaceutical investment decisions.

The major players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc.; (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).

F. Hoffmann-La Roche Ltd. held the leading position in the cancer biomarkers market in 2020. La Roche focuses on innovation to maintain its market share. It invests a significant amount of its revenue in R&D activities for this purpose. These investments are used to develop new and innovative products. The company’s major share comes from the US. With its high R&D capabilities, excellent balance sheet, and asset quality, the company is expected to witness a higher growth rate in the forecast period.

Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202

North America is the largest regional market for global cancer biomarkers market

The global market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2020, North America accounted for the largest share of the global market. The North American market's growth can be attributed to the correlation between an increasing population and increased research activities.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more

Cell Lysis Market Outlook: Trends, Opportunities, and Challenges

-
The global cell lysis market size is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2020, at a CAGR 7.2% from 2021 to 2026. The growth of this market is driven by increasing government funding for research, high prevalence of diseases, and growing focus on personalized medicines Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=260138321 Opportunity: Growing opportunity in emerging markets Emerging countries such as China, Brazil, Mexico, and India present significant opportunities for players in the cell lysis market. The major reasons for this are the increasing prevalence of chronic diseases, improvements in infrastructure facilities for research, and favorable legislation for cell-based research in emerging countries. Due to this, key industry players strengthen their presence in emerging countries like China by establishing new facilities and R&D and innovation centers in the region. Challenge: Survival of small pla...
Read more